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Among 518 patients with a complete record of the epineph-
rine administration route, the percentage of patients receiv-
ing it by intramuscular (IM) injection, subcutaneous (SC) in-
jection, intravenous (IV) bolus injection, or IV continuous in-
fusion was 16.9, 31.5, 43.5, and 8.1%, respectively. Among 
the 427 patients with a record of both the administration 
route and the dosing, an overdose was more likely with IV 
bolus (94.1%) in contrast to IM injection (56.6%;  p < 0.001) or 
SC injection (43.7%;  p < 0.001). Among the patients analyzed 
for CAE ( n = 349), 17 patients accounted for 19 CAE, and 13 
(76.5%) of these patients were overdosed with epinephrine. 
 Conclusion: Underuse, inappropriate IV bolus use, and over-
dosing were the 3 major problems with epinephrine use in 
DIA in China. Educational training for health care profession-
als on the appropriate use of epinephrine in managing ana-
phylactic reactions is suggested.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: Few studies assessing the use of epinephrine 
in drug-induced anaphylaxis (DIA) in the hospital setting are 
available. We utilized the Beijing Pharmacovigilance Data-
base (BPD) to evaluate the appropriateness of epinephrine 
for DIA management.  Methods: DIA cases collected in the 
BPD from January 2004 to December 2014 were adjudicated 
and analyzed for demographics, causative drugs, clinical 
signs, outcomes, initial treatment, route, dosing, and car-
diovascular adverse events (CAE) of epinephrine.  Results: 
DIA was primarily caused by antibiotics (38.4%), radiocon-
trast agents (11.9%), traditional Chinese medicine injections 
(10.9%), and chemotherapeutic drugs (10.3%). Only 708 
(59.5%) patients received epinephrine treatment. Patients 
who received epinephrine were more likely to experience 
wheezing ( p < 0.001) and respiratory arrest ( p < 0.001). 
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 Anaphylaxis is a severe life-threatening systemic aller-
gic reaction with a sudden onset that usually develops af-
ter exposure to an offending agent. Common triggers of 
anaphylaxis include food, hymenoptera venom, and 
drugs  [1, 2] . Anaphylaxis is a medical emergency requir-
ing rapid recognition and prompt management. Epi-
nephrine is the recommended first-line treatment  [3] , 
and its delayed administration is an important risk factor 
for fatal anaphylaxis  [2, 3] .
 Drugs are one of the most common causes of anaphy-
laxis  [2] . According to a study by Jerschow et al.  [4] , drugs 
were the most common cause of 2,458 anaphylaxis-related 
deaths (58.8%) in the USA from 1999 to 2010. Recent evi-
dence suggests that the prevalence of drug-induced ana-
phylaxis (DIA) in inpatients is approximately 0.03%, with 
a mortality rate of 3–9%  [5] . However, most previous stud-
ies assessing anaphylaxis management have been limited 
to patients presenting to emergency departments (ED)  [6–
11] or outpatient allergy clinics  [12–14] . Very few studies 
have been conducted to assess the use of epinephrine in 
patients who developed DIA in generalized clinical set-
tings. Considering the prevalence and the potential sever-
ity of DIA, it is important for healthcare providers to man-
age DIA patients appropriately in the various clinical set-
tings including outpatient, inpatient, and ED.
 Thus, the objective of our study was to assess the use
of epinephrine in patients who developed DIA in clinical 
settings using the Beijing Pharmacovigilance Database 
(BPD). Cases from the BPD were reported by health care 
professionals for patients who had DIA during patient en-
counters. The outcomes of interests were: (1) to analyze 
whether epinephrine was used and whether it was used as 
an initial treatment (first medication administered) to 
manage anaphylaxis, (2) to assess the route of administra-
tion (intramuscular [IM], subcutaneous [SC], intrave-
nous [IV] bolus, or IV continuous infusion) and the dose 
utilized, and (3) to analyze whether any relationship exists 
between the dose used and the incidence of cardiovascular 
adverse events (CAE) associated with epinephrine. 
 Materials and Methods 
 Data Sources 
 The BPD used in this study was provided by the Beijing Ad-
verse Drug Reaction Monitoring Center. The BPD contains rec-
ords of severe adverse drug event (ADE) cases reported from 94 
hospitals in the Beijing region. Its intent is to obtain well-defined, 
standardized data of affected patients experiencing ADE in the 
Beijing region of China. In each clinical setting (inpatient, outpa-
tient, and ED), ADE are typically reported by physicians, phar-
macists, and nurses to the respective pharmacy department. The 
widely accepted World Health Organization-Uppsala Monitoring 
Center (WHO-UMC) criteria were used to assess causality, and 
Certain and Probable/Likely categories were applied for the iden-
tification of an offending agent  [15] . Once a case is confirmed as a 
severe ADE  [16] (defined as at least one of the following outcomes: 
death, life-threatening symptoms, initial or prolonged hospitaliza-
tion, disability or permanent damage, congenital anomaly or birth 
defect, requirement of intervention to prevent permanent impair-
ment or damages, and other serious medical events), the patient’s 
data are electronically reported to the BPD by a pharmacist. BPD 
reports include the following information: the severity of the ADE, 
demographic variables (gender, age, current disease, history of 
ADE, and history of family member ADE), triggering prescrip-
tions (brand and generic name, formulation, dose, unit, frequency, 
route, initial and end dates, and indication), and a description
of the ADE. The ADE information includes the reporting time,
the category (anaphylaxis, pneumonia, gastrointestinal bleeding, 
myocardial infarction, etc.), the severity (moderate or severe), the 
onset date, a detailed description (symptoms, lab data, treatment, 
etc.), and the outcome (death, recovery, or improvement). 
 This study was exempt from further review by the Institutional 
Review Board of Peking University Third Hospital. Informed con-
sent was not required from patients because this was a retrospec-
tive study using only deidentified data. 
 Database Inquiry 
 We downloaded the BPD database for the period covering Jan-
uary 1, 2004, to December 31, 2014, and assembled a base cohort 
that included all patients with a reported drug-induced acute al-
lergic reaction or anaphylaxis using the following search terms: 
“anaphylaxis,” “anaphylactic shock,” “allergy,” “allergic reaction,” 
and “hypersensitivity.” Prior to excluding mild hypersensitivity re-
actions from the base cohort, mutually exclusive definitions for 
drug-related allergic reactions and anaphylaxis using standard def-
initions  [3, 6] were created by 2 physicians, i.e., an emergency phy-
sician (B.W.) and a pediatric allergist (Y.X.) (detailed information 
on the definition and severity of anaphylaxis is shown in online 
suppl. Appendix 1; see www.karger.com/doi/10.1159/000475498 
for all online suppl. material). Patients with acute allergic reactions 
(grade 1) had only cutaneous involvement, whereas patients with 
anaphylaxis were those presenting with grade 2 or 3 reactions; pa-
tients with grade 2 reactions had mild-to-moderate manifestations 
of anaphylaxis, and those with grade 3 reactions had severe pre-
sentations with cutaneous, gastrointestinal, and potentially life-
threatening respiratory or cardiovascular signs and symptoms  [6] . 
 Then the search terms “anaphylaxis,” “anaphylactic reaction,” 
“shock,” “convulsion,” “cardiac arrest,” “respiratory arrest,” “cya-
nosis,” and “death” were used to  identify patients with a potential 
anaphylaxis (grade 2 and 3 reactions). Eligibility required a com-
plete record that included the patient’s age, gender, trigger medi-
cations, anaphylactic symptoms, and treatment. Approximately 
14.9% of the patients were excluded due to incomplete records. 
 Data Extraction 
 For patients with a potential anaphylaxis identified by the 
search terms in the BPD, we developed a data extraction form to 
validate the diagnosis and severity of anaphylaxis and the use of 
epinephrine. The following free-text information was collected: 
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(1) demographic variables and trigger prescriptions, (2) anaphy-
lactic symptoms from different organ systems according to previ-
ous guidelines and literature  [3, 10, 17, 18] , (3) drugs that were 
used to treat the anaphylaxis (nonepinephrine anaphylaxis treat-
ment included corticosteroids, antihistamines, and bronchodila-
tors), and (4) the use of epinephrine (whether it was used as an 
initial treatment, the administration route, the dosing, and adverse 
events). We pretested the extraction form on database records 
from 250 patients and revised the form based on this pretest. Then, 
2 trained extractors independently performed the extraction to en-
sure consistency; discrepancies were resolved by an investigator 
with experience in standardized medical record extraction (T.W.).
 Adjudication 
 The physician adjudicators (B.W. and Y.X.) independently re-
viewed the information extracted from each case, determining the 
diagnosis of anaphylaxis and the case severity, as well as any CAE 
associated with the use of epinephrine. Physician reviewers used 
the published clinical diagnosis of anaphylaxis  [1] and the severity 
definition  [6] as a gold standard and referred to a recent publica-
tion by Campbell et al.  [19] to judge the occurrence of epinephrine 
adverse events. Disagreement was dealt with through discussion. 
Patients with an acute allergic reaction were excluded and only 
those who met the diagnostic criteria for anaphylaxis were includ-
ed in the analysis. 
 Study Design 
 The frequency of the initial administration route of epineph-
rine was assessed according to the severity of anaphylaxis reported. 
To analyze overdosage of epinephrine, epinephrine overdose for 
adults was defined as a dose that exceeded the recommended dose, 
i.e., 0.01 mg/kg body weight, with a maximum dose of 0.5 mg for 
IM and SC injections or 0.1 mg given by IV bolus  [19–23] . Accord-
ingly, the initial epinephrine dosing for adults was analyzed by dif-
ferent administration routes (IM, SC, and IV) and categorized as 
nonoverdose or overdose ( ≤ 0.5 vs. >0.5 mg for both IM and SC, 
and  ≤ 0.1 vs. >0.1 mg for IV bolus). The initial pediatric epineph-
rine dosing was categorized as nonoverdose or overdose  [21, 24, 
9,425 patients with drug-induced hypersensitivity were included in
the base cohort by using the search terms “anaphylaxis,” “anaphylactic
reaction,” “allergy,” “allergic reaction,” and “hypersensitivity”
(January 1, 2004 to December 31, 2014)
7,836 patients with an allergic reaction but not one so severe
as to constitute anaphylaxis were excluded by using the search terms
“anaphylaxis,” “anaphylactic reaction,” “severe,” “shock,” “convulsion,”
“hypotension,” “cardiac arrest,” “respiratory arrest,” “cyanosis,” and “death”
1,189 patients with adjudicated drug-induced anaphylaxis were
included in the retrospective analysis:
 708 received epinephrine
 481 received no epinephrine
1,589 patients with a potential drug-induced anaphylaxis were included
236 patients were excluded by screening symptoms of anaphylaxis
in ADE description:
 9 had missing information on anaphylactic symptoms
 43 had missing information on age
 167 had missing information on drug of choice to treat anaphylaxis
 17 were duplicate individuals
1,353 patients were included for physicians’ adjudication
164 patients were excluded by physicians’ adjudication
 28 had an inadequate description of anaphylactic symptoms
 55 had an allergic reaction but not one so severe as to constitute
  anaphylaxis
 21 were primary disease-caused symptoms
 55 were adverse drug events rather than anaphylaxis
 5 were infusion reactions
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25] based on weight-based dosing ( ≤ 0.01 vs. >0.01 mg/kg for IM 
and SC, with a maximum dose of 0.5 mg, or 0.001 mg/kg for the 
IV bolus route, with a maximum dose of 0.1 mg). When body 
weights were not available, pediatric IM/SC epinephrine dosing 
was assessed according to the child’s age group (<6, 6–12, or >12 
years) as suggested in the literature  [21] . For IV bolus injections, 
age was used to estimate the body weight  [26] to calculate the dose. 
In both adults and children, overdosing with IV continuous infu-
sion was not analyzed since continuous infusion is usually titrated 
to clinical effects and not all of the information necessary to calcu-
late the total dose was available. 
 The inclusion criteria for evaluation of CAE of epinephrine 
were: (1) records reporting both the administration route and the 
dosing of epinephrine (35.2% patients with missing values were 
excluded), (2) signs and symptoms of cardiovascular complica-
tions that developed after epinephrine administration where the 
onset was temporally related (within several minutes or noted on 
the next set of vital signs) to epinephrine administration, and
(3) no concurrent use of epinephrine-like medications (e.g., nor-
epinephrine and dopamine) or reporting of CAE prior to the use 
of such epinephrine-like drugs. CAE were defined according to 
Campbell et al.  [19] . Hypertension was considered an adverse 
event if there was a recorded systolic blood pressure  ≥ 180 mm Hg 
or a diastolic blood pressure  ≥ 120 mm Hg. Cardiac ischemia re-
quired both a documented troponin T level elevation and symp-
toms suggestive of cardiac ischemia, such as chest tightness, pres-
sure, or pain (detailed information is shown in online suppl. Ap-
pendix 2). 
 Variables that influenced the choice of therapy (epinephrine or 
nonepinephrine) for DIA patients were identified. The key base-
line information, organ system involvements, and other nonepi-
nephrine acute therapies to treat anaphylaxis in epinephrine and 
nonepinephrine users were compared. 
 Statistical Analysis  
 The statistical analysis was performed using SPSS version 22 
(SPSS Inc., USA). Continuous variables were subjected to normal-
ity tests using a single-sample Kolmogorov-Smirnov test, and data 
with a normal distribution were expressed as means ± SD, those 
with a nonnormal distribution were expressed as medians (range), 
and the dichotomous variables were described as frequencies (%). 
Continuous variables were compared using an independent sam-
ples t test, while dichotomous variables were compared using the 
Pearson χ 2 test or Fisher’s exact test. To identify independent clin-
ical features (risk factors) associated with patients receiving epi-
nephrine, bivariate logistic regression was used to derive OR and 
95% CI of different variables. Variables with  p values <0.2 in the 
bivariate analysis were included in a multivariate logistic regres-
sion analysis using forward stepwise selection processes. All tests 
were 2-tailed, and  p < 0.05 was considered statistically significant.
 Results 
 Demographic and Clinical Characteristics  
 Using our search terms, 9,425 patients with drug-in-
duced hypersensitivity reactions were identified from the 
BPD. Of those, 1,189 patients with adjudicated anaphy-
laxis were included in our analysis ( Fig. 1 ). Among these 
patients, the mean age was 47.6 years, 627 (52.7%) were 
female, and 91 (7.7%) were children (age <18 years) ( Ta-
ble 1 ). Among the 1,172 DIA cases with a clearly reported 
occurrence setting (inpatient, outpatient, or ED), the ma-
jority of the patients (1,128; 96.2%) developed anaphylax-
is during their hospital stays. Forty-three patients present-
 Table 1.  Demographic and clinical characteristics of patients with 
drug-induced anaphylaxis
Variable Value 95% CI
Mean age ± SD, years 47.6 ± 20.1
Patients aged <18 years 91 (7.7) 6.3 – 9.3
Females 627 (52.7) 49.8 – 55.5
Triggersa
Antibiotics 457 (38.4) 36.2 – 43.8
Radiocontrast agents 141 (11.9) 10.2 – 14.3
TCM (injection) 130 (10.9) 9.4 – 13.2
Chemotherapeutic drugs 122 (10.3) 8.8 – 12.4
Biologics 49 (4.1) 3.0 – 5.4
Anesthetics 25 (2.1) 1.3 – 3.0
Plasma substitutes 25 (2.1) 1.3 – 3.0
Parenteral nutrition 20 (1.7) 1.0 – 2.5
Hormones 16 (1.3) 0.8 – 2.1
NSAID 11 (0.9) 0.4 – 1.6
Associationsb 110 (9.3) 7.8 – 11.5
Othersc 82 (6.9) 5.6 – 8.8
Organ system involvement
Mucocutaneous 563 (47.4) 44.6 – 50.5
Respiratory 659 (55.4) 52.5 – 58.3
Gastrointestinal tract 372 (31.3) 28.8 – 33.9
Cardiovascular 996 (83.8) 81.3 – 85.8
Central nervous system 596 (50.1) 47.4 – 53.1
Origin
Inpatient 1,128 (96.2) 95.1 – 97.3
Outpatient 1 (0.1) 0.0 – 0.3
ED 43 (3.67) 2.6 – 5.0
Outcome
ICU admission 73 (6.1) 4.9 – 7.8
Death 39 (3.3) 2.3 – 4.3
 Values are presented as numbers (%) unless otherwise stated. 
Data were available for 708 patients in the epinephrine group and 
481 patients in the nonepinephrine group, and from 1,172 patients 
with a clearly reported occurrence setting (inpatient, outpatient, or 
ED). a Sorted by groups of drugs most frequently implicated in 
drug-induced anaphylaxis. The classification of culprit medica-
tions was based on a publication by Baldo and Pham [5]. b Defined 
as cases in which more than one medication was suspected to cause 
the anaphylaxis, and these medications belonged to different phar-
macotherapy classes. c Only the top 10 common culprit drugs are 
listed; detailed information on the Others category is presented
in online supplementary Appendix 4. TCM, traditional Chinese 
medicine; NSAID, nonsteroidal anti-inflammatory drugs; ICU, 
intensive care unit; ED, emergency department. 
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 Table 2.  Clinical features associated with epinephrine therapy
Variable Epinephrine Nonepine-
phrine
Bivariate analysis  Multivariate analysis
OR (95%) p value O R (95%) p value
N 708 (59.5) 481 (40.5)
Mean age ± SD, years 46.6 ± 20.2 49.1 ± 19.8 0.94 (0.89 – 0.99) 0.033 0.91 (0.86 – 0.97)a 0.003
Patients aged <18 years 62 (8.8) 29 (6.0) 1.50 (0.95 – 2.36) 0.082
Patients aged ≥18 years 646 (91.2) 452 (94.0) reference
Females 368 (52.0%) 259 (53.8%) 0.93 (0.74 – 1.17) 0.526
Current disease
Asthma/COPD 14 (2.0) 5 (1.0) 1.91 (0.68 – 5.34) 0.210
Cardiovascular disease 103 (14.5) 64 (13.3) 1.10 (0.79 – 1.54) 0.570
Hypertension 38 (5.4) 22 (4.6) 1.18 (0.69 – 2.02) 0.553
Mucocutaneous symptoms 346 (48.9) 217 (45.1) 1.16 (0.92 – 1.47) 0.203
Flushing 120 (16.9) 100 (20.8) 0.78 (0.58 – 1.04) 0.094 0.70 (0.52 – 0.96) 0.024
Pruritus 137 (19.4) 88 (18.3) 1.07 (0.80 – 1.44) 0.648
Diffuse urticaria 179 (25.3) 96 (20.0) 1.36 (1.03 – 1.80) 0.033 1.43 (1.06 – 1.91) 0.018
Angioedema 70 (9.9) 34 (7.1) 1.44 (0.94 – 2.21) 0.091
Conjunctivitis 50 (7.1) 27 (5.6) 1.28 (0.79 – 2.07) 0.319
Gastrointestinal tract symptoms 204 (28.8) 168 (34.9) 0.75 (0.59 – 0.97) 0.026
Emesis 125 (17.7) 97 (20.2) 0.85 (0.63 – 1.14) 0.268
Nausea 138 (19.5) 113 (23.5) 0.79 (0.60 – 1.04) 0.097
Abdominal cramping 41 (5.8) 32 (6.7) 0.86 (0.54 – 1.39) 0.543
Diarrhea 6 (0.8) 11 (2.3) 0.36 (0.13 – 0.99) 0.040
Respiratory symptoms 431 (60.9) 228 (47.4) 1.73 (1.37 – 2.18) <0.001
Rhinorrhea 8 (1.1) 2 (0.4) 2.74 (0.58 – 12.95) 0.186
Cough 26 (3.7) 12 (2.5) 1.49 (0.74 – 2.98) 0.257
Voice change 37 (5.2) 25 (5.2) 1.01 (0.60 – 1.69) 0.983
Dyspnea 138 (19.5) 105 (21.8) 0.87 (0.65 – 1.15) 0.326
Wheezing 216 (30.5) 91 (18.9) 1.88 (1.42 – 2.49) <0.001 1.96 (1.47 – 2.62) <0.001
Cyanosis 129 (18.2) 55 (11.4) 1.73 (1.23 – 2.42) 0.001
Respiratory arrest 68 (9.6) 16 (3.3) 3.09 (1.77 – 5.39) <0.001 3.67 (2.07 – 6.49) <0.001
Hypoxemia 69 (9.7) 39 (8.1) 1.22 (0.81 – 1.85) 0.335
Cardiovascular symptoms 596 (84.2) 400 (83.2) 1.08 (0.79 – 1.47) 0.639
Hypotension 587 (82.9) 398 (82.7) 1.03 (0.76 – 1.40) 0.857
Cardiac arrest 44 (6.2) 9 (1.9) 3.48 (1.68 – 7.19) <0.001
Incontinence 34 (4.8) 31 (6.4) 0.73 (0.44 – 1.21) 0.221
Central nervous system 350 (49.4) 246 (51.1) 0.93 (0.74 – 1.18) 0.563
Presyncope 186 (26.3) 129 (26.8) 0.97 (0.75 – 1.26) 0.834
Syncope 204 (28.8) 146 (30.4) 0.93 (0.72 – 1.20) 0.567
Convulsions 53 (7.5) 39 (8.1) 0.92 (0.60 – 1.41) 0.693
Other medications to treat anaphylaxis
Corticosteroid 612 (86.4) 365 (75.9) 2.03 (1.50 – 2.74) <0.001 2.02 (1.48 – 2.76) <0.001
Bronchodilator 19 (2.7) 21 (4.4) 0.60 (0.32 – 1.14) 0.114 0.44 (0.23 – 0.84) 0.013
Antihistamine 197 (27.8) 147 (30.6) 0.88 (0.68 – 1.13) 0.307
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ed to an ED, and only 1 patient developed anaphylaxis in 
the outpatient setting and did not receive any treatment 
( Table 1 ). Among the 1,128 inpatients, the number of pa-
tients who received anaphylaxis treatment in an ED and 
in a non-ED setting was 123 and 1,005, respectively. The 
top 4 triggers of DIA were antibiotics (38.4%), radiocon-
trast agents (11.9%), traditional Chinese medicine injec-
tions (10.9%), and chemotherapeutic drugs (10.3%). The 
majority of patients (83.8%) experienced cardiovascular 
anaphylactic symptoms (82.8, 4.5, and 5.5% for hypoten-
sion, cardiac arrest, and incontinence, respectively). The 
percentage of patients who developed mucocutaneous 
compromise, respiratory compromise, and central ner-
vous system symptoms was 47.4, 55.4, and 50.1%, respec-
tively. Only 31.3% of the patients had gastrointestinal ana-
phylactic symptoms. Overall, 73 (6.1%) patients were ad-
mitted to an intensive care unit and 39 (3.3%) patients 
died of anaphylaxis during hospitalization.
 Analysis of Therapies for the Treatment of 
Anaphylaxis 
 Of the 708 patients (59.5%) who received epinephrine 
treatment ( Table 2 ), 699 had adequate documentation for 
analysis. Among them, 518 patients (74.1%) were admin-
istered epinephrine as an initial treatment, and 409 of 518 
patients were coadministered corticosteroids. Of the 518 
patients, 26 were excluded since they presented cardiac or 
respiratory arrest prior to the administration of epineph-
rine. The number of patients who received IM, SC, IV 
bolus injection, and IV continuous infusion was 83 
(16.9%), 155 (31.5%), 214 (43.5%), and 40 (8.1%), respec-
tively ( Table 3 ). The median dosing for the IM, SC, and 
IV bolus injection routes was 1.0 (0.10–5.00), 0.5 (0.10–
3.00), and 1.0 mg (0.04–5.00), respectively. Of the 1,189 
anaphylactic patients, 977 (82.2%) received corticoste-
roids, and for 904 (92.5%) of them it was the initial ther-
apy; 344 (28.9%) received antihistamines, and only 40 
(3.4%) received bronchodilators.
 Patients who received epinephrine during the course 
of anaphylactic treatment did not differ significantly from 
those who did not receive it with regard to gender or cur-
rent disease ( Table 2 ). In contrast, there was a significant 
difference between those who received epinephrine and 
those who did not in terms of age (mean 46.6 vs. 49.1 
years,  p = 0.032), risk of mortality (34 vs. 5 patients, OR 
4.81; 95% CI 1.87–12.39), and intensive care unit admis-
sion (53 vs. 20 patients, OR 1.86; 95% CI 1.10–3.16). The 
severity of anaphylaxis was significantly different be-
tween the epinephrine group and the nonepinephrine 
group. There was a higher proportion of respiratory ar-
rest (OR 3.09; 95% CI 1.77–5.39) and cardiac arrest (OR 
3.48; 95% CI 1.68–7.19) in the epinephrine group com-
pared to the nonepinephrine group. In cases of death in 
the epinephrine group, 19 of 34 (55.9%) patients experi-
enced the onset of respiratory or cardiac arrest prior to 
the administration of epinephrine. Fifteen of 34 (44.1%) 
patients did not receive epinephrine as the initial treat-
ment (online suppl. Appendix 3). Among 9 patients who 
received epinephrine as the initial treatment prior to res-
piratory or cardiac arrest, 2 were treated in community 
hospitals and underwent a referral process, and 3 experi-
enced contrast media-induced anaphylaxis, resulting in 
severe anaphylaxis within 10 min. In the multivariate 
analysis, clinical features associated with receiving epi-
nephrine were age (OR per 10-year increase in age: 0.91; 
95% CI 0.86–0.97), flushing (OR 0.70; 95% CI 0.52–0.96), 
diffuse urticaria (OR 1.43; 95% CI 1.06–1.91), wheezing 
(OR 1.96; 95% CI 1.47–2.62), and respiratory arrest (OR 









IV continuous infusion 
(n = 40)
Mild to moderate 15 (18.1) 24 (15.5) 25 (11.7) 4 (10.0)
Severe 68 (81.9) 131 (84.5) 189 (88.3) 36 (90.0)
 Values are presented as numbers (%). Data were available for 518 patients in the epinephrine group with 
clearly documented administration routes (among these, 26 patients with cardiac or respiratory arrest prior to 
administration of epinephrine were excluded). The percentage of patients with IM injection, SC injection, IV 
bolus, and IV continuous infusion is 16.9, 31.5, 43.5, and 8.1%, respectively. IM, intramuscular; SC, subcutane-
ous; IV, intravenous. A significant difference was noted in the use of the different administration routes (p < 
0.001). Overall, there was no significant difference in the percentage of patients with severe anaphylaxis between 
each administration route group (χ2 = 2.931, p = 0.402). 
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3.67; 95% CI 2.07–6.49). Patients who received epineph-
rine were also more likely to receive corticosteroids (OR 
2.02; 95% CI 1.48–2.76) and less likely to receive bron-
chodilators (OR 0.44; 95% CI 0.23–0.84). 
 Analysis of the Initial Administration Route and the 
Initial Dosing of Epinephrine 
 There was a significant difference in the use of differ-
ent administration routes ( p < 0.001), but there was no 
significant difference in terms of anaphylaxis severity be-
tween the administration routes ( p = 0.402;  Table  3 ). 
There was a significant difference between overdose rates 
per administration route ( p < 0.001;  Table 4 ). An over-
dose was more likely with the IV bolus route (94.1%) 
compared to IM (56.6%,  p < 0.001) and SC routes (43.7%, 
 p < 0.001). There was no association with anaphylaxis se-
verity for any administration route ( p = 0.441;  Table 4 ). 
Among a total of 178 patients who experienced periop-
erative DIA, 78 patients received epinephrine adminis-
tration with a clearly documented administration route, 
including 2 (2.6%) via the IM route, 7 (9.0%) via the SC 
route, 20 (25.6%) via IV continuous infusion, and 49 
(62.8%) via IV bolus.
 Analysis of CAE of Epinephrine 
 Among a total of 349 patients eligible for analysis of CV 
complications associated with epinephrine ( Table 5 ), 17 
patients developed 19 CAE, and 13 (76.5%) of them were 
overdosed. Patients who received IM epinephrine had no 
adverse events, 2 (11.8%) patients who received SC epi-
nephrine had arrhythmia events, and 15 (88.2%) patients, 
including 1 child, who received an IV bolus injection had 
17 CV events. Patients who received an epinephrine IV 
bolus (9.62%) were more likely to have adverse CV events 
than patients who received epinephrine via IM (0.00%,
 p = 0.016) or SC (1.64%,  p = 0.006) injections. 
 Discussion 
 As far as we know, our study is the first to assess epi-
nephrine use in patients with DIA using a large pharma-
covigilance database from China. Use of the BPD permit-
ted the collection of data on patients who received epi-
nephrine for DIA in both ED and non-ED settings. 
Therefore, we are able to present the largest community-
based cohort of patients with DIA. To our knowledge, 
this is the first study to evaluate epinephrine use in pa-
tients with DIA in a variety of clinical settings. The num-
ber of patients treated in an ED was lower than the num-
ber of inpatients and, because the BPD database includes 
patients with drug adverse events only, other triggers 
(food, venom, etc.) of anaphylaxis from ED were not in-
cluded in our study. Consistent with previous studies  [4, 
5, 27, 28] , the most common triggers of DIA in our pa-
tient population were antibiotics, radiocontrast agents, 
and chemotherapeutic drugs. Notably, our data suggests 
that, in addition to these known triggers, traditional Chi-
nese medicine injections are one of the top triggers of 
DIA in Beijing, which is consistent with a recent study by 
Jiang et al.  [11] . Further studies regarding the safety of 
traditional Chinese medicine injections are thus warrant-
ed  [29] . A high proportion of patients developed cardio-
vascular symptoms (83.8%), and the mortality rate of 
 Table 4.  Route of epinephrine administration and overdose according to the severity of anaphylaxis
Severity of 
anaphylaxis
IM injection (n = 76) SC injection (n = 142)  IV bolus (n = 187)
overdose nonoverdose p value overdose nonoverdose p value overd ose nonoverdose p value
Mild to moderate 10 (23.3) 3 (9.1) 0.104 12 (19.4) 10 (12.5) 0.263 20 (11.4) 2 (18.2) 0.843
Severe 33 (76.7) 30 (90.9) 50 (80.6) 70 (87.5) 156 (88.6) 9 (81.8)
 Values are presented as numbers (%) unless otherwise stated. Among 427 patients with a clearly reported administration route (IM 
injection, SC injection, or IV bolus) and dose of epinephrine (among these, 22 patients with cardiac or respiratory arrest prior to ad-
ministration of epinephrine were excluded). The initial epinephrine dosing for adults was categorized as nonoverdose or overdose (≤0.5 
vs. >0.5 mg for both IM and SC, and ≤0.1 vs. >0.1 mg for IV bolus). IM, intramuscular; SC, subcutaneous; IV, intravenous. Overall, there 
was no significant difference regarding the severity of anaphylaxis for each administration route (χ2 = 1.638, p = 0.441). There was no 
significant difference in the percentage of severe anaphylaxis between the overdose and nonoverdose groups in each administration 
route group. Overall, there was significant difference regarding the overdose rate for each administration route (χ2 = 103.944, p < 0.001). 
IV bolus was more likely to be associated with overdose compared to IM injection (p < 0.001) and SC injection (p < 0.001). There was 
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3.3% was comparable to those of previous studies  [5, 30] . 
Most cases of DIA developed during patient hospitaliza-
tions and were managed by non-ED health care provid-
ers. The analysis suggests that epinephrine use in patients 
with DIA could be improved in the region studied. 
 Utilization of Epinephrine in Anaphylaxis 
Management 
 Epinephrine should be administered to anaphylaxis pa-
tients as a first-line treatment because a delayed adminis-
tration has been shown to result in poor outcomes and 
fatality  [10, 20] . Corticosteroids are not effective in acute 
anaphylaxis management  [2, 3, 20, 31] , and neither are 
antihistamines  [31–33] . Overall, epinephrine is underused 
for DIA in the Beijing region, which is in line with previ-
ous studies  [11, 34] . Our data indicates a low rate (59.5%) 
of epinephrine use and a suboptimal timing of use, with 
only 74.1% of patients receiving it as the initial treatment. 
Clinicians are more inclined to administer epinephrine to 
patients with respiratory symptoms (e.g., respiratory ar-
rest and wheezing). We observed a higher mortality rate 
in epinephrine users (34 vs. 5), which was probably due to 
a delayed administration of epinephrine (in epinephrine 
users, 56% of the death cases experienced respiratory or 
cardiac arrest prior to epinephrine administration, and 
47% of the death cases did not receive epinephrine as the 
initial treatment). This demonstrated the importance of 
early use of epinephrine for severe anaphylactic patients. 
Although the rate of use of antihistamines was not high 
(28.9%), the use of corticosteroids was considerable (977 
of 1,189; 82.2%). Among the patients who received corti-
costeroids, the number of patients who received cortico-
steroids as a first-line treatment was substantial (904 of 
977; 92.5%). The importance of a timely administration of 
epinephrine should be stressed in DIA management. 
 Assessment of the Epinephrine Administration Route 
 There is significant discrepancy between guidelines  [2, 
3] and actual practice in the Beijing region regarding the 
administration route of epinephrine. Based on a previous 
pharmacokinetic study in children not experiencing ana-
phylaxis, IM injection of epinephrine into the anterolat-
eral thigh results in a higher and more rapid peak plasma 
concentration compared to SC injection in the arm  [35] , 
and thus IM should be the preferred administration route 
 [3] . However, more patients in our study received SC epi-
nephrine compared to IM administration (31.5 vs. 16.9%). 
IV continuous infusion of epinephrine should only be 
given to patients not responding to IM injection  [3] . Nev-
ertheless, our data showed that in 8.1% of cases the initial 
administration route of epinephrine was by continuous 
infusion. A possible explanation is that physicians’ lack of 
knowledge regarding anaphylaxis treatment guidelines 
contributes to a high utilization of the IV route of admin-
istration. IV bolus administration of epinephrine should 
be avoided whenever possible due to the risk of cardiac 
 Table 5.  Cardiovascular adverse events associated with routes of epinephrine administration
Cardiovascular 
adverse eventsa
IM injection (n = 0) SC injection (n = 2) IV bolus (n = 17)b
overdose nonoverdose overdose nonoverdose over dose nonoverdose
Hypertension 0 0 0 0 8 (47.1) 1 (5.9)
Arrhythmia 0 0 1 (50.0) 1 (50.0) 5 (29.4) 2 (11.8)
Ischemia 0 0 0 0 1 (5.9) 0
Stroke 0 0 0 0 0 0
Angina 0 0 0 0 0 0
 Values are presented as numbers (%). We included 349 patients for cardiovascular event analysis, including 
71 patients with IM injection, 122 with SC injection, and 156 with IV bolus. IM, intramuscular; SC, subcutane-
ous; IV, intravenous; cardiovascular adverse events. a The signs and symptoms of cardiovascular complications 
that developed after epinephrine administration where the onset was temporally related (within several min or 
noted on the next set of vital signs) to the epinephrine administration. b One patient presented with both hyper-
tension and arrhythmia, and 1 patient presented with both arrhythmia and myocardial ischemia. One pediatric 
patient presented with arrhythmia. Overall, there was a significant difference regarding the CAE rate in each 
administration route (χ2 = 16.728, p < 0.001). IV bolus was more likely to be associated with CAE compared to 
SC injection (p = 0.006) and IM injection (χ2 = 5.835, p = 0.016). There was no significant difference in overdose 
rates between IM injection and SC injection (p = 0.532).
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arrhythmias and the increased potential for inappropri-
ate dosing  [19, 36–38] . It should only be considered when 
a patient is experiencing an actual or impending cardio-
vascular collapse and is unresponsive to an epinephrine 
continuous infusion or when an epinephrine continuous 
infusion  is not feasible due to time constraints  [20] . How-
ever, our data showed that IV bolus injection was the 
most frequently (43.5%) used initial administration route; 
it was used about 5.4 times more than the IV continuous 
infusion route (8.1%). The data showed that there was no 
statistically significant relationship between the severity 
of the anaphylaxis and the treatment administration 
route selected. In this analysis, we excluded patients with 
cardiac or respiratory arrest prior to administration of 
epinephrine, since the route and dose of epinephrine 
should follow the guidelines for resuscitations. Further-
more, a relatively low proportion of perioperative cases 
could not account for the highly frequent choice of the IV 
route. The data support a need for further education of 
clinicians regarding the appropriate route of epinephrine 
administration in the management of anaphylaxis. 
 Implications of Overdosing of Epinephrine and CAE 
 The observation of the significantly higher risk of 
overdose subsequent to IV bolus administration of epi-
nephrine is consistent with prior research  [19] . Our find-
ing of a significantly higher risk of cardiovascular com-
plications associated with IV bolus injection compared to 
IM administration confirms the relative safety of IM ad-
ministration reported by Campbell et al.  [19] . Excluding 
patients with multiple presentations of CAE, 12 of the 15 
patients (80%) who developed adverse CAE were in the 
overdose group, suggesting  that bolus administration of 
IV epinephrine is associated with inappropriate dosing 
 [19, 35–38] .
 Limitations 
 Our retrospective analysis was based on self-reported 
cases by health care professionals to the BPD database, 
and therefore our study has the following limitations:
(1) we could not assess the prevalence of anaphylaxis in 
the region studied as we did not have information for the 
total patient base, (2) reporting biases may exist (most 
reported cases were hospitalized patients in the non-ED 
setting, and only severe anaphylactic cases may have been 
reported), (3) we may not have included all DIA patients 
in the BPD (cases were missed if clinicians did not report 
using terms related to allergy or anaphylaxis or hypersen-
sitivity; e.g., a patient had bronchospasm, wheeze, and 
vomiting but was not described as “allergy” by clinicians 
when reporting to the BPD, and some reported cases were 
not included due to a lack of sufficient information), and 
(4) the causative drugs were identified using WHO-UMC 
criteria  [15] . The drug hypersensitivity diagnostic work-
up could increase sensitivity when determining the caus-
ative drug for anaphylaxis  [39–43] . However, such in-
formation was not recorded in the BPD. Despite this,
the method we used should be robust against some of
the reporting biases; rigorous inclusion/exclusion criteria 
were utilized and all potential anaphylaxis cases were ad-
judicated by trained physician/allergists, and only pa-
tients with confirmed anaphylaxis and a complete data 
record were included in the analysis. 
 Conclusion 
 Our study suggests that epinephrine use in DIA man-
agement in Beijing should be improved. Underuse of epi-
nephrine, overuse of IV bolus administration, and over-
dosing of epinephrine are the 3 major problems. Our re-
sults highlight the risk of overdosing and CAE associated 
with IV bolus administration. Targeted educational pro-
grams on the utilization of consensus anaphylaxis man-
agement guidelines for optimal patient care are necessary.
 Disclosure Statement 
 Til Stürmer received investigator-initiated research funding 
and support as principal investigator (R01/R56 AG023178) from 
the National Institute on Aging (NIA), and as coinvestigator (R01 
CA174453, R01 HL118255, and R21-HD080214) from the Nation-
al Institutes of Health (NIH). He also receives salary support as 
director of the Comparative Effectiveness Research (CER) Strate-
gic Initiative from the NC TraCS Institute, he is a recipient of the 
UNC Clinical and Translational Science Award (UL1TR001111), 
and he receives support as director of the Center for Pharmaco-
epidemiology (current members: GlaxoSmithKline, UCB BioSci-
ences, and Merck) and research support from pharmaceutical 
companies (Amgen and AstraZeneca) to the Department of Epi-
demiology, University of North Carolina at Chapel Hill. Dr. 
Stürmer does not accept personal compensation of any kind from 
any pharmaceutical company. He owns stock in Novartis, Roche, 
BASF, AstraZeneca, and Novo Nordisk. The remaining authors 
have no conflict of interests to disclose. This research received no 










 1 Sampson HA, Munoz-Furlong A, Campbell 
RL, et al: Second symposium on the definition 
and management of anaphylaxis: summary 
report – Second National Institute of Allergy 
and Infectious Disease/Food Allergy and 
Anaphylaxis Network symposium. J Allergy 
Clin Immunol 2006; 117: 391–397. 
 2 Simons FE, Ebisawa M, Sanchez-Borges M, et 
al: 2015 update of the evidence base: World 
Allergy Organization anaphylaxis guidelines. 
World Allergy Organ J 2015; 8: 32. 
 3 Muraro A, Roberts G, Worm M, et al: Ana-
phylaxis: guidelines from the European Acad-
emy of Allergy and Clinical Immunology. Al-
lergy 2014; 69: 1026–1045. 
 4 Jerschow E, Lin RY, Scaperotti MM, McGinn 
AP: Fatal anaphylaxis in the United States, 
1999–2010: temporal patterns and demo-
graphic associations. J Allergy Clin Immunol 
2014; 134: 1318–1328.e7. 
 5 Baldo BA, Pham NH: Classification and de-
scriptions of allergic reactions to drugs; in: 
Drug Allergy: Clinical Aspects, Diagnosis, 
Mechanisms, Structure-Activity Relation-
ships. New York, Springer, 2013. 
 6 Brown AF, McKinnon D, Chu K: Emergency 
department anaphylaxis: a review of 142 pa-
tients in a single year. J Allergy Clin Immunol 
2001; 108: 861–866. 
 7 Cianferoni A, Novembre E, Mugnaini L, et al: 
Clinical features of acute anaphylaxis in pa-
tients admitted to a university hospital: an 11-
year retrospective review (1985–1996). Ann 
Allergy Asthma Immunol 2001; 87: 27–32. 
 8 Lieberman P, Decker W, Camargo CA Jr, 
Oconnor R, Oppenheimer J, Simons FE: 
SAFE: a multidisciplinary approach to ana-
phylaxis education in the emergency depart-
ment. Ann Allergy Asthma Immunol 2007; 
 98: 519–523. 
 9 Oren E, Banerji A, Clark S, Camargo CA Jr: 
Food-induced anaphylaxis and repeated epi-
nephrine treatments. Ann Allergy Asthma 
Immunol 2007; 99: 429–432. 
 10 Baalmann DV, Hagan JB, Li JT, Hess EP, 
Campbell RL: Appropriateness of epineph-
rine use in ED patients with anaphylaxis. Am 
J Emerg Med 2016; 34: 174–179. 
 11 Jiang N, Yin J, Wen L, Li H: Characteristics of 
Anaphylaxis in 907 Chinese patients referred 
to a tertiary allergy center: a retrospective 
study of 1,952 episodes. Allergy Asthma Im-
munol Res 2016; 8: 353–361. 
 12 Jarvinen KM, Sicherer SH, Sampson HA, 
Nowak-Wegrzyn A: Use of multiple doses of 
epinephrine in food-induced anaphylaxis in 
children. J Allergy Clin Immunol 2008; 122: 
 133–138. 
 13 Kelso JM: A second dose of epinephrine for 
anaphylaxis: how often needed and how to 
carry. J Allergy Clin Immunol 2006; 117: 464–
465. 
 14 Korenblat P, Lundie MJ, Dankner RE, Day 
JH: A retrospective study of epinephrine ad-
ministration for anaphylaxis: how many dos-
es are needed? Allergy Asthma Proc 1999; 20: 
 383–386. 
 15 The Uppsala Monitoring Centre: The use of 
the WHO-UMC system for standardized case 
causality assessment. https://www.who-umc.
org/media/2768/standardised-case-causali-
ty-assessment.pdf (accessed March 11, 2017). 
 16 US Food and Drug Administration: What is a 
serious adverse event? https://www.fda.gov/
S a f e t y / M e d W a t c h / H o w T o R e p o r t /
ucm053087.htm (accessed March 3, 2017). 
 17 Simons FE, Sheikh A: Anaphylaxis: the acute 
episode and beyond. BMJ 2013; 346:f602. 
 18 Brown SG: Clinical features and severity grad-
ing of anaphylaxis. J Allergy Clin Immunol 
2004; 114: 371–376. 
 19 Campbell RL, Bellolio MF, Knutson BD, et al: 
Epinephrine in anaphylaxis: higher risk of 
cardiovascular complications and overdose 
after administration of intravenous bolus epi-
nephrine compared with intramuscular epi-
nephrine. J Allergy Clin Immunol 2015; 3: 76–
80. 
 20 Campbell RL, Li JT, Nicklas RA, Sadosty AT: 
Emergency department diagnosis and treat-
ment of anaphylaxis: a practice parameter. 
Ann Allergy Asthma Immunol 2014; 113: 
 599–608. 
 21 Soar J, Pumphrey R, Cant A, et al: Emergency 
treatment of anaphylactic reactions – guide-
lines for healthcare providers. Resuscitation 
2008; 77: 157–169. 
 22 Lieberman P, Nicklas RA, Randolph C, et al: 
Anaphylaxis – a practice parameter update 
2015. Ann Allergy Asthma Immunol 2015; 
 115: 341–384. 
 23 Kemp SF, Lockey RF, Simons FER, et al: Epi-
nephrine: the drug of choice for anaphy-
laxis – a statement of the World Allergy Or-
ganization. Allergy 2008; 63: 1061–1070. 
 24 Hegenbarth MA: Preparing for pediatric 
emergencies: drugs to consider. Pediatrics 
2008; 121: 433. 
 25 Lane RD, Bolte RG: Pediatric anaphylaxis. Pe-
diatr Emerg Care 2007; 23: 49–56. 
 26 Tinning K, Worth AC: Make your best guess: 
an updated method for paediatric weight esti-
mation in emergencies. Emerg Med Australas 
2007; 19: 528–534. 
 27 Demoly P: Drug hypersensitivity. Immunol 
Allergy Clin North Am 2014; 34:xv–xvi. 
 28 Ribeiro-Vaz I, Marques J, Demoly P, Polonia 
J, Gomes ER: Drug-induced anaphylaxis: a 
decade review of reporting to the Portuguese 
Pharmacovigilance Authority. Eur J Clin 
Pharmacol 2013; 69: 673–681. 
 29 Guo YJ, Wang DW, Meng L, Wang YQ: Anal-
ysis of anaphylactic shock caused by 17 types 
of traditional Chinese medicine injections 
used to treat cardiovascular and cerebrovas-
cular diseases. Biomed Res Int 2015; 2015: 
 420607. 
 30 Fisher M, Baldo BA: Anaphylaxis during an-
aesthesia: current aspects of diagnosis and 
prevention. Eur J Anaesthesiol 1994; 11: 263–
284. 
 31 Choo KJ, Simons E, Sheikh A: Glucocor-
ticoids for the treatment of anaphylaxis:
Cochrane systematic review. Allergy 2010; 65: 
 1205–1211. 
 32 Sheikh A, Ten BV, Brown SG, Simons FE:
H1-antihistamines for the treatment of ana-
phylaxis: Cochrane systematic review. Allergy 
2007; 62: 830–837. 
 33 Sheikh A, ten Broek VM, Brown SG, Simons 
FE: H1-antihistamines for the treatment of 
anaphylaxis with and without shock. Coch-
rane Database Syst Rev 2007; 1:CD006160. 
 34 Asai Y, Yanishevsky Y, Clarke A, et al: Rate, 
triggers, severity and management of anaphy-
laxis in adults treated in a Canadian emergen-
cy department. Int Arch Allergy Immunol 
2014; 164: 246–252. 
 35 Simons FE, Roberts JR, Gu X, Simons KJ: Epi-
nephrine absorption in children with a his-
tory of anaphylaxis. J Allergy Clin Immunol 
1998; 101: 33–37. 
 36 Manivannan V, Campbell RL, Bellolio MF, 
Stead LG, Li JT, Decker WW: Factors associ-
ated with repeated use of epinephrine for the 
treatment of anaphylaxis. Ann Allergy Asth-
ma Immunol 2009; 103: 395–400. 
 37 Karch SB: Coronary artery spasm induced
by intravenous epinephrine overdose. Am J 
Emerg Med 1989; 7: 485–488. 
 38 Kanwar M, Irvin CB, Frank JJ, Weber K, Ros-
man H: Confusion about epinephrine dosing 
leading to iatrogenic overdose: a life-threat-
ening problem with a potential solution. Ann 
Emerg Med 2010; 55: 341–344. 
 39 Rebelo Gomes E, Geraldes L, Gaspar Â,  et al: 
Hypersensitivity reactions to nonsteroidal 
anti-inflammatory drugs among adults: clini-
cal features and risk factors for diagnosis con-
firmation. Int Arch Allergy Immunol 2016; 
 171: 269–275. 
 40 Kepil Özdemir S, Öner Erkekol F, Ünal D, et 
al: Management of hypersensitivity reactions 
to proton pump inhibitors: a retrospective ex-
perience. Int Arch Allergy Immunol 2016; 
 171: 54–60. 
 41 Blanca-López N, Pérez-Sánchez N, Agúndez 
JA, et al: Allergic reactions to metamizole: im-
mediate and delayed responses. Int Arch Al-
lergy Immunol 2016; 169: 223–230. 
 42 Guvenir H, Dibek Misirlioglu E, Capanoglu 
M, et al: Proven non-β-lactam antibiotic al-
lergy in children. Int Arch Allergy Immunol 
2016; 169: 45–50. 
 43 Pineda F, Ariza A, Mayorga C, et al: Role of 
histamine release test for the evaluation of pa-
tients with immediate hypersensitivity reac-
tions to clavulanic acid. Int Arch Allergy Im-
munol 2015; 168: 233–240. 
 
